Published in Science on June 20, 1986
Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J (1987) 4.33
Insulin-like growth factors and cancer. Br J Cancer (1992) 2.31
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A (1987) 1.61
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 1.56
Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer (1988) 1.55
The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol (2011) 1.27
Unregulated expression of c-Jun or c-Fos proteins but not Jun D inhibits oestrogen receptor activity in human breast cancer derived cells. EMBO J (1991) 1.23
Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A (1987) 1.22
ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma. Breast Cancer Res (2011) 1.12
Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci U S A (1996) 1.10
Expression of Q227L-galphas in MCF-7 human breast cancer cells inhibits tumorigenesis. Proc Natl Acad Sci U S A (1998) 1.01
Epidermal growth factor receptor status of histological sub-types of breast cancer. Br J Cancer (1988) 0.96
Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways. Mol Cell Biol (1993) 0.95
Endocrine resistance in breast cancer - An overview and update. Mol Cell Endocrinol (2015) 0.93
Expression of ecto-5'-nucleotidase (CD73) in normal mammary gland and in breast carcinoma. Br J Cancer (1991) 0.86
Rapid regulation of c-myc protooncogene expression by progesterone in the avian oviduct. Proc Natl Acad Sci U S A (1988) 0.83
Identification of a pituitary factor responsible for enhancement of plasminogen activator activity in breast tumor cells. Proc Natl Acad Sci U S A (1986) 0.80
Growth-inhibitory effects of epidermal growth factor on human breast cancer and carcinoma of the esophagus transplanted into nude mice. Ann Surg (1990) 0.80
Autocrine growth factors and solid tumor malignancy. West J Med (1991) 0.80
Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells. Br J Cancer (2000) 0.80
Expression of epidermal growth factor receptor (proto-oncogene c-erbB-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 cases. Arch Gynecol Obstet (1993) 0.79
17-beta-estradiol increases mitogenic activity of medium from cultured preadipocytes of massively obese persons. J Clin Invest (1989) 0.79
Clonogenic growth and hormone sensitivity of benign and malignant breast tissues. Br J Cancer (1987) 0.75
Breast cancer (1) N Engl J Med (1992) 4.79
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep (1985) 2.97
Multicolour spectral karyotyping of mouse chromosomes. Nat Genet (1996) 2.90
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (1998) 2.85
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A (1984) 2.42
c-Myc in breast cancer. Endocr Relat Cancer (2000) 2.32
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
alpha 2-macroglobulin adsorbed to colloidal gold: a new probe in the study of receptor-mediated endocytosis. J Cell Biol (1981) 2.19
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer (2000) 2.14
Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev (1987) 2.07
Mechanism of action of glucocorticoids. Metabolism (1974) 2.04
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (1990) 2.00
Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res (1978) 1.97
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem (1999) 1.93
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation. Breast Cancer Res Treat (1983) 1.80
Amantadine and dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-mediated endocytosis of alpha 2-macroglobulin. Proc Natl Acad Sci U S A (1982) 1.76
Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol (1987) 1.72
Breast conservation versus mastectomy: distress sequelae as a function of choice. J Clin Oncol (1989) 1.70
Isolation and characterization of a highly enriched preparation of receptosomes (endosomes) from a human cell line. Proc Natl Acad Sci U S A (1983) 1.68
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther (2001) 1.64
Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem (1999) 1.62
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A (1987) 1.61
Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy. J Natl Cancer Inst (1996) 1.60
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res (1986) 1.58
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol (2001) 1.57
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res (1990) 1.57
Oestrogen-responsive human breast cancer in long term tissue culture. Nature (1975) 1.56
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med (1978) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem (2001) 1.49
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
Prelysosomal divergence of transferrin and epidermal growth factor during receptor-mediated endocytosis. Biochemistry (1983) 1.46
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Matrix metalloproteinase inhibitors. Invest New Drugs (1997) 1.43
Breast cancer (2). N Engl J Med (1992) 1.39
Growth factors in breast cancer. Endocr Rev (1995) 1.37
Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem (1997) 1.36
Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst (1992) 1.36
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res (1991) 1.36
Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res (1979) 1.35
Receptor-mediated endocytosis in cultured fibroblasts: cryptic coated pits and the formation of receptosomes. J Histochem Cytochem (1981) 1.35
Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer (1980) 1.34
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A (1976) 1.32
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res (1993) 1.32
Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res (1988) 1.32
Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. J Biol Chem (1984) 1.31
Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol (1988) 1.31
Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst (1993) 1.30
Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene (2000) 1.29
Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep (1979) 1.27
A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice. Genes Chromosomes Cancer (1999) 1.26
Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res (1999) 1.26
Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science (1985) 1.26
Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst (2001) 1.26
Estrogen receptor in adult male rat liver. Endocrinology (1978) 1.26
Oestrogen receptors in human malignant melanoma. Lancet (1976) 1.26
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res (1999) 1.25
Expression and function of angiopoietin-1 in breast cancer. Br J Cancer (2000) 1.24
Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis (1994) 1.24
Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res (2001) 1.23
Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A (1987) 1.22
Competitive protein binding assay for methotrexate. Proc Natl Acad Sci U S A (1975) 1.21
Tamoxifen retinopathy. Cancer Treat Rep (1978) 1.21
Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res (1985) 1.20
Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology (1985) 1.20
Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology (1986) 1.19
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer (2004) 1.19
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.19
Breast cancer (3). N Engl J Med (1992) 1.18
Glucocorticoid-binding proteins in human acute lymphoblastic leukemic blast cells. J Clin Invest (1973) 1.17
Binding and internalization of 125I-alpha 2-macroglobulin by cultured fibroblasts. J Biol Chem (1981) 1.17
Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem (1982) 1.17
Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol Carcinog (1992) 1.17
High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. N Engl J Med (2000) 1.17
Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer (1980) 1.15
Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol (1987) 1.14